MLTX
MoonLake Immunotherapeutics
Latest close $17.55 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 2 of 2 parsed filing(s)| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates CIK0000080255 | Mar 31, 2025 observed May 14, 2025 filed · 44d Schedule 13G amendment | Reported reduction | 3.0M -369.4K | 12.00% 0.00 pts | $39.07 | $36.99 | $17.55 |
| T. Rowe Price Associates CIK0000080255 | Dec 31, 2024 observed Feb 14, 2025 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 3.3M | 12.00% | $54.15 | $43.21 | $17.55 |